

PATENT APPLICATION/PCT
Attorney Docket No. 702-020040

6/A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application :
Eric P. KRENNING :
Marion DE JONG :
Roelf VALKEMA :
International Application :
No. PCT/EP00/06917 :
International Filing Date :
17 July 2000 :
Priority Date Claimed :
16 July 1999 :
Serial No. Not Yet Assigned :
Filed Concurrently Herewith :

INHIBITION OF RENAL UPTAKE OF
MOLECULES THAT ARE
POTENTIALLY DAMAGING FOR THE
KIDNEY

Pittsburgh, Pennsylvania
January 16, 2002

PRELIMINARY AMENDMENT

Box PCT
Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified patent application as follows:

IN THE SPECIFICATION:

On page 1, after the title, please insert the following section headings:

BACKGROUND OF THE INVENTION

AN 1. Field of the Invention

Before the paragraph beginning at page 1, line 7, please insert the following section heading:

A2 2. Description of the Related Art

Before the paragraph beginning at page 4, line 8, please insert the following section heading:

A3 SUMMARY OF THE INVENTION

Please replace the partial paragraph beginning at page 4, line 8 with the following rewritten paragraph:

A4 The present invention is a combination of:

Before the paragraph beginning at page 4, line 25, please insert the following section headings and specification paragraphs:

BRIEF DESCRIPTION OF THE DRAWINGS

AS Figure 1 shows the ratio between [¹¹¹In-DTPA-D-Phe¹]octreotide uptake in various organs in the presence or absence of 1 L lysine/arginine infusion (25/25 g; administered over 4 hours);

Figure 2 shows the ration between [¹⁷⁷Lu-DOTA, Tyr³]octreotate uptake in various organs in the presence or absence of 1 L lysine/arginine infusion (25/25 g; administered over 4 hours);

Figure 3 shows the ratio between [¹¹¹In-DTPA-D-Phe¹]octreotide uptake in various organs in the presence or absence of 1 L glucose/saline solution, administered over 4 hours; and

Figure 4 shows between [¹¹¹In-DTPA-D-Phe¹]octreotide uptake in the left kidney after a 0.5 + 3.5 hour infusion of various amino acid compositions.